Current setbacks cannot prevent gene-editing companies from advancing closer to “one-and-done” cures and new products.

Some outside researchers were less reserved. Clinical trials using CRISPR gene editing have been underway for nearly a decade. But like most trials, they focused on broad groups of patients.

A US court just put ownership of CRISPR back in play The CRISPR patents are back in play. Yesterday, the US Court of Appeals for the Federal Circuit said scientists Jennifer Doudna and Emmanuelle ...

A baby boy with a devastating genetic disease is thriving after becoming the first known person to receive a bespoke, CRISPR therapy-for-one, designed to correct his specific disease-causing ...

13. Leading trade organizations representing the makers of cell and gene therapies are calling for a 10-year international moratorium on the use of CRISPR and other DNA-editing tools to create ...

CRISPR Therapeutics has an approved gene-therapy treatment still in its early growth stages. The company isn't profitable, but has a strong cash position, which can help buy a lot of time. One of ...

CRISPR Therapeutics has an approved gene-therapy treatment still in its early growth stages. One of them is CRISPR Therapeutics (NASDAQ: CRSP). Its financials haven't been looking all that ...

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing ...

The CRISPR specialist said that a single 50mg infusion of NTLA-2002 – which switches off a gene involved in the potentially life-threatening inflammatory attacks that characterise HAE ...

The specialist in CRISPR-based gene editing – co-founded by Nobel Prize winner Jennifer Doudna – said it is focusing on NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...